Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-101 food effect study in healthy volunteers
NCT06887010Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ABBV-101 (2 arms), sponsored by AbbVie Inc. Primary endpoints: Adverse Events at 45 days, Maximum Observed Plasma Concentration at 21 days and 3 more. Started Mar 2025; status: completed.
02
Drugs
ABBV-101
Beyond the preview
Go deeper on NCT06887010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06887010.